Ligne de temps

Ophélie Godon
Ingénieur(e) de Recherche
19 janv. 2024
publication

A monoclonal antibody collection for C.difficile typing ?

Lire plus
06 avr. 2023
publication

Conditional neutrophil depletion challenges their contribution to mouse models of anaphylaxis.

Lire plus
13 mars 2023
news

New publication – A vaccine targeting human IL-4 and IL-13 protects against asthma in humanized mice

Lire plus
17 févr. 2023
publication

A vaccine targeting human IL-4 and IL-13 protects against asthma in humanized mice.

Lire plus
01 janv. 2023
publication

Isolation methods determine human neutrophil responses after stimulation.

Lire plus
03 sept. 2021
publication

Neutrophil-specific gain-of-function mutations in Nlrp3 promote development of cryopyrin-associated periodic syndrome

Lire plus
22 janv. 2021
publication

The role of IgG subclasses and platelets in experimental anaphylaxis.

Lire plus
14 sept. 2018
team

Groupe: Friederike JONSSON

Lire plus
13 avr. 2018
publication

Platelets expressing IgG receptor FcγRIIA/CD32A determine the severity of experimental anaphylaxis.

Lire plus
26 avr. 2016
publication

IgG subclasses determine pathways of anaphylaxis in mice

Lire plus
22 oct. 2015
project

ERC-2013-CoG – 616050_MyeloSHOCK – Role of myeloid cells, their mediators and their antibody receptors in allergic shock (anaphylaxis) using humanized mouse models and clinical samples

Lire plus
21 oct. 2015
project

DROPmAbs – Deep-mining of antibody repertoires using droplet-based microfluidics combined with barcoded deep sequencing for diagnostics and therapeutic antibody discovery

Lire plus
20 oct. 2015
project

Role of platelets and their interactions in allergic diseases

Lire plus
17 oct. 2015
project

Antibody-based anti-tumor immunotherapy

Lire plus
23 juil. 2015
publication

Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes

Lire plus
11 mai 2015
team

Anticorps en Thérapie et Pathologie

Lire plus
26 nov. 2014
publication

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice

Lire plus